Anthelmintic compositions and method of using same



United States Patent 3,060,088 AN'I'I-IELMIN'IIC COMPOSITIONS AND METHOD OF USING SAME Philip Arthur Kingshury, Bcrkhamsted, and Roy Vivian Foster, Tring, England, assignors to Cooper, Mc- Dougall 8i Robertson Limited, Berkhamsted, England, a British company No Drawing. Filed Nov. 7, 1960, Ser. No. 67,495 Claims priority, application Great Britain Nov. 20, 1959 8 Claims. (Cl. 167-53) The present invention relates to compositions having anthelmintic activity and to the manufacture thereof.

It has been found that a composition containing one or more ammonium cations of Formula I in the form of one or more salts and a relatively small proportion of an ester of Formula II has a greater than additive efiect against infestations of Trichostrongylus spp., in particular T. colubriformis and T. vilrinus, in sheep.

(in. (It) In Formula II:

R and R are the same or different and each is an alkyl group such as a methyl, ethyl or isopropyl group;

X is an oxygen or sulphur atom; and

R is a hydrogen or halogen atom.

The relatively small proportion of an ester of Formula II in a dose is preferably not greater than the minimum toxic dose level to the host; that is, between 7.0 mg. and 25.0 mg. for sheep, depending on the particular ester and the mode and frequency of administration. The phrase "greater than additive effect is to be understood as meaning that the elfect of the simultaneous administration to an animal of the components of the said composition at a specified dose level is greater than the sum of the effects of each of the components at the respective specified dose levels when administered separately to separate animals; and therefore the therapeutic index of the composition is greater than that of each of the active components.

Preferably the composition contains by weight 100 parts of one or more cations of Formula I in the form of one or more salts and 0.05 to 25.0 parts of one or more esters of Formula II, and in particular 1.0 to 10.0 parts of one or more esters of Formula II. The preferred cations of Formula I are those in which R is a hydrogen atom and M is the benzyl or thenyl group. The preferred salts of the cation of Formula I are the chloride, bromide, iodide, citrate, p-toluenesulphonate, p-chlorobenzcnesulphonate, 2-hydroxy-3-naphthoate and embonate; especially preferred are those which are spar- 3,060,088 Patented Oct. 23, 1962 ingly soluble in water at 20 C., that is, the p-toluenesulphonate, p-chlorobenzene-sulphonate, 2 hydroxy 3- naphthoate, and embonate, which are known to be less toxic to the host than the more soluble salts. The preferred esters of formula II are those in which R and R are both ethyl groups, especially 3-chloro-4-methyl-7oxycoumarin-0,0-diethylthiophosphoric acid ester.

The effective doserange of the composition to be administered to the host depends on a number of variable factors, for example the particular cation of Formula I, the particular salt of the cation of Formula I, the particular ester of Formula II, the parasite to be controlled, the maturity and health of the particular host, and the mode and frequency of administration of the composition. The amount of the cation of Formula I in a dose of the eomposition is preferably not greater than 1,000 mg./kg., generally not greater than 500 mg./lig., and not less than 20 mg./kg. The amount of an ester of Formula II in a dose of the composition is preferably not greater than 5.0 mgJkg. and not less than 0.5 mg./ kg. for administration to sheep. The preferred dose of the compositioncontains 30 to 250 rng'./kg. of a cation of Formula I and 1.0 to 5.0 mg./kg. of an ester of Formula II.

The composition is preferably administered orally in any acceptable preparation containing the composition and an acceptable carrier therefor. Fine powders or granules may contain diluents and dispersing and surface active agents, and may be presented in a draft or drench in water or in a syrup; in capsules or cachets in the dry state or in a non-aqueous suspension, when a suspending agent may be included; in tablets, when binders and lubricants may be included; in a suspension in water or a syrup or an oil, or in a water/oil emulsion, when flavouring, preserving, suspending, thickening and emulsifying agent may be included; or in the food of the host of the nematode. The ganules or the tablets may be coated. The preferred preparation for administration are fine dispersible powders, tablets and emulsions. For administration to sheep, the composition or preparation is preferably administered into the fourth abomasum.

According to the present invention in several aspects, there are provided the compositions containing one or more ammonium cations of Formula I in the form of one or more salts and a relatively small proportion of an ester of Formula II, and animal feeding stulfs containing the composition, and the process for the treatment of nematode infestations which comprises administering to the nematode infested locus the composition.

The composition or the preparations containing the composition and an acceptable carrier therefor may be manufactured by any method comprising respectively the mixing together of the active components of the compositions, and the mixing together of the active components of the composition and an acceptable carrier therefor.

The invention will now be described with reference to the following examples, in which the amounts of the constituents are indicated in parts by weight.

Example 1 Percent N-benzyl-N,N-dimethyl-N-2-phenoxyethylammonium Z-hydroxy-Ii-naphthoate 94.5 3-chloro-4-methyl-7-oxyooumarin'0.0-diethylthiophosphoric acid ester 2.5 A wetting and dispersing agent, such as a sodium salt of an alltylarylsulphonic acid 3.0

A fine dispersible powder was prepared by grinding the Z-hydroxy-Ii-naphthoate, mixing some of the salt with the 3 chloro 4 methyl 7 oxycoumarin 0,0 diethylthiophosphorie acid ester and the wetting, dispersing agent, adding the rest of the salt to the mixture, and intimately mixing the resultant mixture.

3 Example 2 Percent N-benzyl-N,N-dimethyl-N-2-phenoxyethy[ammonium Z-hydroxy-J-naphthoate 90.1 3-ehloro-4-methyl-7-oxycoumarin-0,0-diethylthiophosphoric acid ester 2.5 A binding agent, such as starch 4.6 A dispersing agent, such as sodium bicarbonate--- 1.9 A lubricating agent such as talc 0.9

Tablets of the above composition and weighing 5.0 g. were prepared by intimateiy mixing the ingredients together, granulating the mixture, and compressing the granules.

Example3 3 chloro 4 methyl 7 oxycoumarin 0,0 diethylthiophosphoric acid ester (1 part) was mixed with a diatomaceous earth known as "Celite 209" (4 parts) in a ball mill. The mixture (3.33 parts) was mixed with a dispersible powder of N-benzyl-N,N-dimethyl-N- 2 phenoxyethylammonium 2 hydroxy 3 naphthoate (96.67 parts).

Example4 3 chloro 4 methyl 7 oxycoumarin 0,0 diethylthiophosphoric acid ester (10 parts) was mixed in a mill with a diatomaceous earth known as "Celite 209" (40 parts). Kaolin (49 parts) and a wetting agent containing a sulphonate and ltnown as Perminal BX" (1 part) were added, and the whole thoroughly mixed. This wettable powder (1.8 parts) was then mixed with a dispersible powder of N-benzyl-N,N-dimcthyl-N-Z-phenoxyethylamrnonium 2-hydroxy-3-naphthoate (10 parts).

Example 5 Similar preparations to those described in Examples 1, 2, 3 and 4 were made using relative proportions of N benzyl N,N dimethyl N 2 phenoxyethylammonium chloride, bromide, citrate. p-toluenesulphonate. pchlorobenzenesulphonate or embonate instead of the 2-hydroxy-3-naphthoate. With the more soluble salts, relatively less of the wetting and dispersing agent was required.

Example6 Similar preparations to those described in Examples 1, 2, 3 and 4 were made using relative proportions of N,N dimethyl N 2 phenoxyethyl N 2' thenylammonium p-chlorobenzenesulphonate, N-benzyl-N,N- dimethyl-N-2-o-methylphenoxyethylammonium iodide or embonate, N o chlorobenzyl N.N dimethyl N 2- o-methylphenoxyethylammonium iodide or embonate or 4:4'-diaminostilbene-2:2-disulphonate, N-o-chlorobenzyl N,N dimethyl N 2 o chlorophenoxyethylammonium p-chlorobenzenesulphonate, or N-o-methylbenzyl N,N dimethyl N 2 o methylphenoxyethylammonium chloride or p-toluenesulphonate instead of the N benzyl N,N dimethyl N 2 phenoxyelhylammonium Z-hydroxy-J-naphthoate.

Example 7 Similar preparations to those described in Examples 1, 2, 3 and 4 were made using 3-chloro-4-methylor 4-methyl-7-oxycoumarin-0,0-dicthylphosphoric acid ester instead of the 3-chloro-4-methyl-7-oxycoumarin-0,0- diethylthiophosphoric acid ester.

Example 8 Compositions were made by mixing the following components, the amount of each component being specified respectively as the amount in mg./kg. administered to the host.

(a) N benzyl N,N dimethyl N 2 phenoxyethylammonium Z-hydroxy-S-naphthoate and 3'chloro- 4 methyl 7 oxycoumarin 0,0 diethylthiophosphorie acid-ester:

4 (0....-- 134 and 6.2 (xvi) 35 and 2.5 (ii) 67 and 6.2 (xvii) 140 and 2.1) (iii)---- 33 and 6.2 (xviii). 70 and 2.0 (iv) 187 and 6.0 (xix) 35 and 2.0

(v)- 250 and5.8 (xx) 17.5 and 2.0 (vi) 134 and 4.6 (xxi).... 187 and 1.5 (vii) 67 and 4.6 (xxii) 140 and 1.25 (viii) 187 and 4.5 (xxiii)- 70 and 1.25 (ix)- 250 and 4.3 (xxiv) 35 and 1.25 (x) 134 and 3.1 (XML... 140 and 1.0 (xi) 187 and 3.0 (xxvi) 70 and 1.0 (xii).... 250 and 2.9 (xxvii) 35 and 1.0 (xiii) 140 and 2.5 (xxviii) 140 and 0.625 (xiv) and 2.5 (xxix) 70 and 0.625

(ML... 70 and 2.5

(b) N-benzy1-N,N-dimethyl N-2 phenoxyethylammonium p-toluenesulphonate and 3-chloro-4-methyl-7-oxycoumarin-QO-dicthylthiophosphoric acid ester:

(2') and 2.5 (ii) 70 and 2.5 (iii) 35 and 2.5

(e) N-benzyl-N,N-dimethyl-N-2 phenoxyethylammonium chloride, bromide, citrate, p-chlorobcnzenesulphm nate or embonatc and 3-chloro-4-methyl-7-oxycoumarin- 0,0-diethylthiophosphoric acid ester:

140 and 2.5

(d) N-benzyl-N,N-dimethy1-N-2 phenoxyethylammonium 2-hydroxy-3-naphthoate and 3-chloro-4-methy1-7- oxycoumarin-QO-diethylphosphoric acid ester:

(i) 140and2.5 (ii) 70and 2.5 (iii) l40and 2.0

(e) N-benzyl-N,N-dimethyl-N-2 phenoxycthylammonium 2-hydroxy-3-naphthoate and 3-bromo4-methyl-7- oxycoumarimQO-diethylthiophosphoric acid ester:

140 and 5 Example 9 N-benzyl-N,N'dimethyI-N-Z phenoxyethylammonium citrate and N-o-methylbenzyl-N,N-dimethyl-N-2-o-methylphenoxyethylammonium p-toluenesulphonate were prepared from respectively the ammonium chloride and iodide by double decomposition, and had melting points of respectively 126 to 131 C. and 157 to 162' C.

We claim:

I. A composition containing a therapeutically acceptable salt of a cation of the formula:

wherein M is selected from the class consisting of a thenyl group and a benzyl group containing an ortho substituent selected from the class consisting of hydrogen, halogen and the methyl, ethyl, methoxy, methylmercapto, nitro and nitroso groups and (1) wherein R is selected from the class consisting of hydrogen. halogen, the methyl and nitro groups, when M is a thenyl group and (2) wherein R is selected from the class consisting of hydrogen, halogen, the methyl, ethyl, methoxy, methylmercapto, formyl, acetyl, cyano, nitro and nitroso groups, when M is a benzyl group; and a relatively small proportion of an ester of the formula:

wherein R and R are each a lower alkyl group, X is selected from the class consisting of oxygen and sulphur atoms, and R is selected from the class consisting of hydrogen and halogen atoms.

2. A composition as claimed in claim 1 wherein there are 100 parts of the defined cation in the form of a therapeutically acceptable salt, and 0.05 to 25.0 parts of the defined ester.

3. A composition as claimed in claim I wherein the ester has both R and R as eth'yl groups.

4. A composition as claimed in claim 1 wherein the ester is 3-chloro-4-methyl- 7 -oxycoumarin-0,0-diethylthiophosphon'c acid ester.

5. A composition as claimed in claim 1 wherein the cation is the N-benzyl-N,N-dimethyl-N-Z-phenoxyethylammonium cation.

6. A composition as claimed in claim 1 wherein the cation is the N,N-dimethyl-N-2-phenoxyethyl-N-2"thenylammonium cation.

7. An animal feeding stuff containing a composition as claimed in claim 1.

8. A process for the treatment of nematode infestations which comprises administering to the host of the nematode infested locus a composition as claimed in claim 1.

References Cited in the file of this patent UNITED STATES PATENTS Copp Dec. 22, 1959 OTHER REFERENCES UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3.060.088 October 23, 1962 Philip Arthur Kingsbury et a1.

It is hereby certified that error appears in the ab ent requiring correction and that the said Letters Paten corrected below.

ove numbered patt should read as Column 1, lines 20 to 24,

the formula should appear as shown below instead of as in th e patent:

1 R \Hs sighed and sealed this 19th day of March 1963.

(SEAL) Attest:

DAVID L. LADD ESTON G. JOHNSON Co .zn .ss. 0.|er 0 Pa .elns 

1. A COMPOSITION CONTAINING A THERAPEUTICALLY ACCEPTABLE SALT OF A CATION OF THE FORMULA: 